目的 探討金水寶膠囊聯(lián)合復(fù)方α-酮酸片治療慢性腎功能衰竭的臨床療效。方法 選取2012年3月-2016年3月在寶雞市第二人民醫(yī)院接受治療的慢性腎功能衰竭患者196例，隨機(jī)分為對(duì)照組（98例）和治療組（98例）。所有患者均給予常規(guī)治療。對(duì)照組口服復(fù)方α-酮酸片，4片/次，3次/d。治療組在對(duì)照組的基礎(chǔ)上口服金水寶膠囊，3粒/次，3次/d。兩組患者均連續(xù)治療2個(gè)月。比較兩組臨床療效，內(nèi)生肌酐清除率（Ccr）、血肌酐（Scr）、血清尿素氮（BUN）、轉(zhuǎn)化生長(zhǎng)因子-β1（TGF-β1）和Ⅳ型膠原蛋白（IV-C）。結(jié)果 治療后，對(duì)照組和治療組總有效率分別為83.67%和94.90%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組Scr、BUN水平均較同組治療前顯著降低，Ccr水平則升高，同組治療前后差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療后，治療組這些觀察指標(biāo)顯著優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組TGF-β1和IV-C水平均低于同組治療前，同組治療前后差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療后，治療組TGF-β1、IV-C水平顯著低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 金水寶膠囊聯(lián)合復(fù)方α-酮酸片治療慢性腎功能衰竭具有顯著的療效，可明顯改善患者腎功能，降低尿TGF-β1和IV-C水平，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To observe the clinical effect of Jinshuibao Capsules combined with Compound α-Ketoacid Tablets in treatment of chronic renal failure. Methods Patients (196 cases) with chronic renal failure in Baoji No. 2 People's Hospital from March 2012 to March 2016 were divided into control (98 cases) and treatment (98 cases) groups. All patients were given conventional treatment. Patients in the control group were po administered with Compound α-Ketoacid Tablets, 4 tablets/time, 3 times daily. Patients in the treatment group were po administered with Jinshuibao Capsules on the basis of control group, 3 grains/time, 3 times daily. The patients in two groups were treated for 2 months. After treatment, the efficacy was evaluated, and Ccr, Scr, BUN, TGF-β1, and IV-C levels in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 83.67% and 94.90%, respectively, and there were differences between two groups (P<0.05). After treatment, Scr and BUN levels in two groups were significantly decreased, and Ccr level was increased, and the difference was statistically significant in the same group (P<0.05). After treatment, the observational indexes in the treatment group were significantly better than those in the control group with significant difference between two groups (P<0.05). After treatment, TGF-β1 and IV-C levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). After treatment, TGF-β1 and IV-C levels in the treatment group were significantly lower than those in the control group with significant difference between two groups (P<0.05). Conclusion Jinshuibao Capsules combined with Compound α-Ketoacid Tablets has a clinical curative effect in treatment of chronic renal failure, can significantly improve renal function and reduce urine TGF-β1 and IV-C levels, which has a certain clinical application value.